From The Editor | October 4, 2018

Two Cancer Therapies And Ten CDMOs

Louis Garguilo

By Louis Garguilo, Chief Editor, Outsourced Pharma
Follow Me On Twitter @Louis_Garguilo

Vadim Klyushnichenko, PhD, CSCP, VP Pharmaceutical Development and Quality, California Institute for Biomedical Research (Calibr) and The Scripps Research Institute (TSRI), excels at enumeration.

For example, here’s what he tells us about the services he outsources for Calibr’s bispecific small molecule antibody conjugate  (SMAC), targeting prostate cancer, that is based on a “unique ADC-type structure optimization enabled by unnatural amino acid technology”:

click on graphic to enlarge